TipRanks on MSN

Corbus Pharmaceuticals Announces $70.5M Public Offering

An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On October 30, 2025, Corbus Pharmaceuticals announced an underwritten ...

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today ...

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today ...

ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204

Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Finanznachrichten

Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces Pricing of Public Offering

a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. Forward-Looking Statements Statements in this press release that ...
Endocrinology Advisor

Kidney, CV Outcomes Similar Between Liraglutide, Semaglutide, Dulaglutide in T2D

Kidney and cardiovascular outcomes were similar between liraglutide, dulaglutide, and semaglutide among patients with type 2 diabetes.
eLife

Mechanistic insights into transcriptional regulation of ARHGAP36 expression identify a factor predictive of neuroblastoma survival

This important study examines the potential role of ARHGAP36 transcriptional regulation by FOXC1 in controlling sonic hedgehog signaling in human neuroblastoma. While there are many solid findings ...